A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease

Hormones and Behavior

Volumn 64, Issue 1, 2013, Pages 1-7

  He, Pingping ^a   Ouyang, Xinping ^a   Zhou, Shouhong ^a   Yin, Weidong ^a   Tang, Chaoke ^a   Laudon, Moshe ^b   Tian, Shaowen ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b NEURIM PHARMACEUTICALS LTD   (Israel)

Author keywords

Alzheimer' disease; Melatonin; Memory; Neu P11; Rats

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; MELATONIN; PIROMELATINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HIPPOCAMPUS; LEARNING; MALE; MAZE TEST; MEMORY; MORNING DOSAGE; NONHUMAN; PRIORITY JOURNAL; RAT; TASK PERFORMANCE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CIRCADIAN RHYTHM; COGNITION DISORDERS; INDOLES; MALE; MAZE LEARNING; MELATONIN; MEMORY; PEPTIDE FRAGMENTS; PSYCHOMOTOR PERFORMANCE; PYRANS; RATS; RATS, SPRAGUE-DAWLEY; RECOGNITION (PSYCHOLOGY);

EID: 84878862568     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2013.04.009     Document Type: Article

References (55)

1. Asayama K., Yamadera H., Ito T., Suzuki H., Kudo Y., Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J. Nippon Med. Sch. 2003, 70:334-341.
2. Ball M., Braak H., Coleman P., Dickson D., Duyckaerts C., Gambetti P., Hansen L., Hyman B., Jellinger K., Markesbery W., Perl D., Powers J., Price J., Trojanowski J.Q., Wisniewski H., Phelps C., Khachaturian Z. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging 1997, 18:S1-S2.
3. Barker G.R., Warburton E.C. When is the hippocampus involved in recognition memory?. J. Neurosci. 2011, 31:10721-10731.
4. Bertaina-Anglade V., Drieu-La-Rochelle C., Mocaër E., Seguin L. Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol. Biochem. Behav. 2011, 98:511-517.
5. Boyd-Kimball D., Sultana R., Poon H.F., Lynn B.C., Casamenti F. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid β-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 2005, 132:313-324.
6. Broadbent N.J., Squire L.R., Clark R.E. Spatial memory, recognition memory, and the hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14515-14520.
7. Butterfield D.A., Boyd-Kimball D. Amyloid beta-peptide (1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol. 2004, 14:426-432.
8. Christensen R., Marcussen A.B., Wortwein G., Knudsen G.M., Aznar S. Aβ (1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels. Exp. Neurol. 2008, 210:164-171.
9. 1-42 in the rat hippocampus in vivo. Neuropharmacology 2007, 52:136-145.
10. Colton C.A., Mott R.T., Sharpe H., Xu Q., Van Nostrand W.E., Vitek M.P. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflammation 2006, 3:27.
11. Dere E., Huston J.P., De Souza Silva M. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci. Biobehav. Rev. 2007, 31:673-704.
12. Dubocovich M.L., Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005, 27:101-110.
13. Duyckaerts C., Potier M.C., Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:5-38.
14. Feng Z., Qin C., Chang Y., Zhang J.T. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic. Biol. Med. 2006, 40:101-109.
15. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
16. Giovannini M.G., Scali C., Prosperi C., Bellucci A., Vannucchi M.G., Rosi S., Pepeu G., Casamenti F. β-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol. Dis. 2002, 11:257-274.
17. Gönenç S., Uysal N., Açikgöz O., Kayatekin B.M., Sönmez A., Kiray M., Aksu I., Güleçer B., Topçu A., Semin I. Effects of melatonin on oxidative stress and spatial memory impairment induced by acute ethanol treatment in rats. Physiol. Res. 2005, 54:341-348.
18. Hogan M.V., El-Sherif Y., Wieraszko A. The modulation of neuronal activity by melatonin: in vitro studies on mouse hippocampal slices. J. Pineal Res. 2001, 30:87-96.
19. Hou D.R., Wang Y., Zhou L., Chen K., Tian Y., Song Z., Bao J., Yang Q.D. Altered angiotensin- converting enzyme and its effects on the brain in a rat model of Alzheimer disease. Chin. Med. J. (Engl.) 2008, 121:2320-2323.
20. Jhoo J.H., Kim H.C., Nabeshima T., Yamada K., Shin E.J., Jhoo W.K., Kim W., Kang K.S., Jo S.A., Woo J.I. β-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav. Brain Res. 2004, 155:185-196.
21. Jobim P.F., Pedroso T.R., Werenicz A., Christoff R.R., Maurmann N., Reolon G.K., Schröder N., Roesler R. Impairment of object recognition memory by rapamycin inhibition of mTOR in the amygdala or hippocampus around the time of learning or reactivation. Behav. Brain Res. 2012, 228:151-158.
22. Larson J., Jessen R.E., Uz T., Arslan A.D., Kurtuncu M., Imbesi M., Manev H. Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci. Lett. 2006, 393:23-26.
23. Laudon M., Urade Y., Huang Z. Neu-P11, a novel melatonin agonist: effects on sleep and EEG power spectra in rats. Sleep 2008, 31(Suppl. A):34-35.
24. Liu R.Y., Zhou J.N., van Heerikhuize J., Hofman M.A., Swaab D.F. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease and apolipoprotein E-e4/4 genotype. J. Clin. Endocrinol. Metab. 1999, 84:323-327.
25. Liu R.Y., Gu R., Qi X.L., Zhang T., Zhao Y., He Y., Pei J.J., Guan Z.Z. Decreased nicotinic receptors and cognitive deficit in rats intracerebroventricularly injected with beta-amyloid peptide (1-42) and fed a high cholesterol diet. J. Neurosci. Res. 2008, 86:183-193.
26. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 1997, 23:134-147.
27. Matsubara E., Bryant-Thomas T., Pacheco Quinto J., Henry T.L., Poeggeler B., Herbert D., Cruz-Sanchez F., Chyan Y.J., Smith M.A., Perry G., Shoji M., Abe K., Leone A., Grundke-Ikbal I., Wilson G.L., Ghiso J., Williams C., Refolo L.M., Pappolla M.A., Chain D.G., Neria E. Melatonin increase survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem. 2003, 85:1101-1108.
28. McLarnon J.G., Ryu J.K. Relevance of abeta1-42 intrahippocampal injection as an animal model of inflamed Alzheimer's disease brain. Curr. Alzheimer Res. 2008, 5:475-480.
29. Munoz L., Ralay Ranaivo H., Roy S.M., Hu W., Craft J.M., McNamara L.K., Chico L.W., Van Eldik L.J., Watterson D.M. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J. Neuroinflammation 2007, 4:21.
30. Musshoff U., Riewenherm D., Berger E., Fauteck J.D., Speckmann E.J. Melatonin receptors in rat hippocampus: molecular and functional investigations. Hippocampus 2002, 12:165-173.
31. O'hare E., Weldon D.T., Mantyh P.W., Ghilardi J.R., Finke M.P., Kuskowski M.A., Maggio J.E., Shephard R.A., Cleary J. Delayed behavioral effects following intrahippocampal injection of aggregated Abeta (1-42). Brain Res. 1999, 815:1-10.
32. Olcese J.M., Cao C., Mori T., Mamcarz M.B., Maxwell A., Runfeldt M.J., Wang L., Zhang C., Lin X., Zhang G., Arendash G.W. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J. Pineal Res. 2009, 47:82-96.
33. Palop J.J., Mucke L. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
34. Pappolla M.A., Sos M., Omar R.A., Bick R.J., Hickson-Bick D.L.M., Reiter R.J., Efthimiopoulos S., Robakis N.K. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer's amyloid peptide. J. Neurosci. 1997, 17:1683-1690.
35. Pappolla M.A., Bozner P., Soto C., Shao H., Robakis N.K., Zagorski M., Frangione B., Ghiso J. Inhibition of Alzheimer β-fibrillogenesis by melatonin. J. Biol. Chem. 1998, 273:7185-7189.
36. Paulis L., Simko F., Laudon M. Cardiovascular effects of melatonin receptor agonists. Expert Opin. Investig. Drugs 2012, 21:1661-1678.
37. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego.
38. Poeggeler B., Miravalle L., Zagorski M.G., Wisniewski T., Chyan Y.J., Zhang Y., Shao H., Bryant-Thomas T., Vidal R., Frangione B., Ghiso J., Pappolla M.A. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Aβ peptide. Biochemistry 2001, 40:14995-15001.
39. Ramírez-Rodríguez G., Vega-Rivera N.M., Benítez-King G., Castro-García M., Ortíz-López L. Melatonin supplementation delays the decline of adult hippocampal neurogenesis during normal aging of mice. Neurosci. Lett. 2012, 530:53-58.
40. Rawashdeh O., Maronde E. The hormonal Zeitgeber melatonin: role as a circadian modulator in memory processing. Front. Mol. Neurosci. 2012, 5:27.
41. Rojo L.E., Ferna'ndez J.A., Maccioni A.A., Jimenez J.M., Maccioni R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimers disease. Arch. Med. Res. 2008, 39:1-16.
42. Selkoe D.J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 2004, 6:1054-1061.
43. She M., Deng X., Guo Z., Laudon M., Hu Z., Liao D., Hu X., Luo Y., Shen Q., Su Z., Yin W. Neu-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol. Res. 2009, 59:248-253.
44. Singer C., Tractenberg R.E., Kaye J., Schafer K., Gamst A., Grundman M., Thomas R., Thal L.J. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003, 26:893-901.
45. Skribanek Z., Baláspiri L., Mák M. Interaction between synthetic amyloid-β-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J. Mass Spectrom. 2001, 36:1226-1229.
46. Spuch C., Antequera D., Isabel Fernandez-Bachiller M., Isabel Rodríguez-Franco M., Carro E. A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease. Neurotox. Res. 2010, 17:421-431.
47. Srinivasan V., Kaur C., Pandi-Perumal S., Brown G.M., Cardinali D.P. Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value. Int. J. Alzheimers Dis. 2010, 2011:741974.
48. Tian S.W., Laudon M., Han L., Gao J., Huang F.L., Yang Y.F., Deng H.F. Antidepressant-and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacol. Sin. 2010, 31:775-783.
49. Wang L.M., Suthana N.A., Chaudhury D., Weaver D.R., Colwell C.S. Melatonin inhibits hippocampal long-term potentiation. Eur. J. Neurosci. 2005, 22:2231-2237.
50. Wimo A., Winblad B., Jönsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement. 2010, 6:98-103.
51. Wu Y., Feenstra M., Zhou J.N., Liu R.Y., Toranõ J.S., Van Kan H.J., Fischer D.F., Ravid R., Swaab D.F. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J. Clin. Endocrinol. Metab. 2003, 88:5898-5906.
52. Yalkinoglu Ö., Zisapel N., Nir T., Piechatzek R., Schorr-Neufing U., Bitterlich N., Allgaier C., Oertel R., Kluge A., Laudon M. Phase-I study of the safety, tolerability, pharmacokinetics and sleep promoting activity of Neu-P11, a novel putative insomnia drug in healthy humans. Sleep 2010, 33:A220. (Abstract Supplement).
53. Yamada K., Tanaka T., Han D., Senzaki K., Kameyama T., Nabeshima T. Protective effects of idebenone and α-tocopherol on β-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in β-amyloid-induced neurotoxicity in vivo. Eur. J. Neurosci. 1999, 11:83-90.
54. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.
55. Zhou J.N., Liu R.Y., Kamphorst W., Hofman M.A., Swaab D. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J. Pineal Res. 2003, 35:125-130.